Jane Street
LCTX icon

Jane Street’s Lineage Cell Therapeutics LCTX Stock Holding History

Jane Street’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-24,100
Closed -$40.7K – 11832
2025
Q3 		$40.7K Sell
24,100
-39,800
-62% -$47.1K ﹤0.01% 10401
2025
Q2 		$58K Buy
+63,900
New +$37.9K ﹤0.01% 9142
2022
Q1 		– Sell
-44,900
Closed -$110K – 10700
2021
Q4 		$110K Buy
+44,900
New +$105K ﹤0.01% 9190
2016
Q4 		– Sell
-28,118
Closed -$96K – 4353
2016
Q3 		$96K Buy
+28,118
New +$77.7K ﹤0.01% 3852

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street's LCTX Position: Q2 2026 in Review

Jane Street reduced its Lineage Cell Therapeutics (LCTX) stake by 95% in Q2 2026, selling an estimated $1.3M and leaving 49,783 shares worth $65.2K. The position accounts for ﹤0.01% of the portfolio, ranked #10818.

Jane Street first reported a position in LCTX in Q2 2014 and has held it in 41 quarters since. The position peaked at $1.68M in Q4 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Jane Street held 49,783 shares of Lineage Cell Therapeutics worth $65.2K as of Q2 2026.
  • Jane Street sold 943,425 Lineage Cell Therapeutics shares in Q2 2026, an estimated $1.3M.
  • Lineage Cell Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10818 holding.
  • Jane Street first reported a position in Lineage Cell Therapeutics in Q2 2014 and has held it in 41 quarters since.
  • Jane Street's Lineage Cell Therapeutics position peaked at $1.68M in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.